An Investigation Into the Feasibility of Beetroot Juice Supplementation in People Living With Alzheimer's Disease.

NCT07258004 | Not Yet Recruiting

• 1 other identifier: OMNI Feasibility trial
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if taking a beetroot juice supplement will work in people living with Alzheimer's disease. The main questions it aims to answer are:

• Can people living with Alzheimer's disease realistically drink beetroot juice regularly (for example, is it easy to take, free from side effects and acceptable)?
• Does drinking beetroot juice twice a day improve health in people living with Alzheimer's disease? Researchers will look at how you managed with the beetroot juice, as well as if there were any improvements in your health measures. Participants will:
• Complete testing before and after the intervention for no more than 3 hours each time
• Complete a 1-day food diary before testing
• Take a beetroot juice supplementation twice daily for 1-week
• Keep a note of any problems with the beetroot juice

Conditions

Alzheimer's Disease

Keywords

Nitric oxide; Dementia; Alzheimer's disease; Oral microbiome; Dietary nitrate; Beetroot juice

Outcome Measures

Primary Outcomes (1)

• Feasibility of a beetroot juice intervention in people living with Alzheimer's disease

  Participants will be supported by a carer, friend or family member to complete a semi-structured interview to assess how feasible the trial was. Questions will be based around adherence (e.g. was the beetroot juice taken consistently and at the right times), acceptability/safety (e.g. was the beetroot juice tolerable and would they consider doing it daily if the benefits were proven and were there any adverse effects) and data collection feasibility (e.g. how easy was it to collect and post saliva samples themselves and how much of a burden was the pre and post-testing). Simple Likert scales will also be used to assess acceptability of the beetroot juice.

  From enrolment to the post-intervention testing 8-days later.

Secondary Outcomes (12)

• Changes to oral microbiome pre to post intervention

  From enrolment to the post-intervention testing 8-days later.

• Changes to cognitive function pre and post intervention

  From enrolment to the post-intervention testing 8-days later.

• Changes to nitric oxide metabolism

  From enrolment to the post-intervention testing 8-days later.

• Changes to nitric Oxide metabolism

  From enrolment to the post-intervention testing 8-days later.

• Changes to nitric oxide metabolism

  From enrolment to the post-intervention testing 8-days later.

Study Arms (1)

Beetroot juice supplementation

EXPERIMENTAL

Dietary Supplement: Beetroot juice

Interventions

Beetroot juice DIETARY_SUPPLEMENT

Participants will take a concentrated beetroot juice shot (70ml) twice daily for 1-week. Each shot contains 400mg of dietary nitrate (800mg per day).

Beetroot juice supplementation

Eligibility Criteria

• Age: 65 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Aged 65-85 years
• Mild or Moderate Alzheimer's disease
• Participants must be able to speak, read, and understand English to participate in this study.
• To support adherence, participants are asked to have a carer, partner, friend, or family member available to assist with reminders to take the shots twice daily.

You may not qualify if:

• Advanced or severe Alzheimer's Disease
• Diagnosis of an additional neurological condition
• Have used antibiotics in the last month
• Use of mouthwash in the last month
• Use of medication affecting nitrate metabolism (for example proton pump inhibitors, Isosorbide Mononitrate, Sildenafil or Glyceryl Trinitrate).
• Unable to provide informed consent
• Allergies to beetroot
• Taking part in pharmacological trials

Sponsors & Collaborators

• University of the West of Scotland: lead
• NHS Lanarkshire: collaborator

Study Sites (1)

University of the West of Scotland

Glasgow, Lanarkshire, G72 0LH, United Kingdom

Location

MeSH Terms

Conditions

Alzheimer Disease; Dementia

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• Rachel Kimble

  University of the West of Scotland

  STUDY DIRECTOR

Central Study Contacts

Scott N Findlay

CONTACT

+447909159194; scott.findlay@uws.ac.uk

Rachel Kimble

CONTACT

Rachel.Kimble@uws.ac.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 16, 2025
• First Posted: December 2, 2025
• Study Start: March 1, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: December 2, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)